Monique J. Roobol

Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium

Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project

Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry

Comparison of Magnetic Resonance Imaging–Based Risk Calculators to Predict Prostate Cancer Risk

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer

Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U

Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration

Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study

Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry

Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future

Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis

Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021

A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer

Genetic factors associated with prostate cancer conversion from active surveillance to treatment

Reply to Laura Evangelista and Egesta Lopci’s Letter to the Editor re: Hendrik Van Poppel, Renée Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327–9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy

An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk

Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission

Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan

Introducing PIONEER: a project to harness big data in prostate cancer research

The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor

Additional SNPs improve the performance of a polygenic hazard score for prostate cancer

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019

Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative